T2D status was found to be a highly significant predictor of weight loss efficacy ( P = 2.0 × 10 −73 ; Supplementary Table 4 ), with an average predicted reduction of 2.87 percentage points in BMI loss for people with a T2D diagnosis.
Although the SNP did not achieve significance ( P < 0.001) in any non-European population, the estimated effects were all directionally consistent (Fig. 1c ) and a fixed effect meta-analysis increased the significance of the observed association ( P = 1.1 × 10 −12 ).
In a joint regression model including a snp:drug type interaction term, we determined the difference to be weakly significant ( P = 0.02).